Literature DB >> 9462888

Low concentrations of estradiol reduce beta-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells.

K E Gridley1, P S Green, J W Simpkins.   

Abstract

The present studies were undertaken to determine the role of physiologically relevant concentrations of estrogens on amyloid-induced changes in cell viability, metabolic demands, and lipid peroxidation in response to the toxic fragment of beta-amyloid (betaAP 25-35). To this end, SK-N-SH human neuroblastoma cells were exposed to betaAP 25-35 or betaAP 25-35 plus 17beta-estradiol, and cell viability, media glucose use and lactate production were measured at time points ranging from 3 to 15 h for examination of acute effects, or at 48 and 72 h time points for chronic effects. Addition of betaAP 25-35 to SK-N-SH cells decreased the number of viable cells from 5% at 3 h to 35% at 15 h when compared to vehicle controls. Chronic treatment for 48 and 72 h caused decreases in viable cell number of 70% and 65%, respectively. Paradoxically, both glucose utilization and lactate production were found to be increased for the betaAP-treated cells. Concomitant estrogen treatment was found to be neuroprotective, as the severity of the insult on cell viability was decreased by 40% at 15 h and up to 71% at 72 h. Likewise, the addition of 17beta-estradiol decreased both the glucose use and lactate production of the cells. Chronic treatment with betaAP caused increases in lipid peroxidation over vehicle treated controls of 82% and 78% at 48 and 72 h, respectively, while decreases in peroxidation of 48% were seen with simultaneous estrogen treatment. These results indicate that the neuroprotective effects of estrogens against betaAP-induced toxicity are due in part to their capability to decrease lipid peroxidation and may additionally be attributable to decreasing the metabolic load of the cell.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9462888     DOI: 10.1016/s0006-8993(97)01056-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  23 in total

1.  Glutamate receptor requirement for neuronal death from anoxia-reoxygenation: an in Vitro model for assessment of the neuroprotective effects of estrogens.

Authors:  L L Zaulyanov; P S Green; J W Simpkins
Journal:  Cell Mol Neurobiol       Date:  1999-12       Impact factor: 5.046

Review 2.  Alzheimer's disease in man and transgenic mice: females at higher risk.

Authors:  R S Turner
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons.

Authors:  C A Singer; X A Figueroa-Masot; R H Batchelor; D M Dorsa
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

Review 4.  Allostasis, allostatic load, and the aging nervous system: role of excitatory amino acids and excitotoxicity.

Authors:  B S McEwen
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

5.  Transgene delivery with a cationic lipid in the presence of amyloid beta (betaAP) peptide.

Authors:  P S Ajmani; W Wang; F Tang; M A King; E M Meyer; J A Hughes
Journal:  Neurochem Res       Date:  2001-03       Impact factor: 3.996

6.  Ovarian hormones elicit phosphorylation of Akt and extracellular-signal regulated kinase in explants of the cerebral cortex.

Authors:  M Singh
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 7.  Protective actions of sex steroid hormones in Alzheimer's disease.

Authors:  Christian J Pike; Jenna C Carroll; Emily R Rosario; Anna M Barron
Journal:  Front Neuroendocrinol       Date:  2009-05-07       Impact factor: 8.606

8.  Protein phosphatase 1, protein phosphatase 2A, and calcineurin play a role in estrogen-mediated neuroprotection.

Authors:  Kun Don Yi; James W Simpkins
Journal:  Endocrinology       Date:  2008-06-19       Impact factor: 4.736

9.  Differential mechanisms of neuroprotection by 17 beta-estradiol in apoptotic versus necrotic neurodegeneration.

Authors:  C Harms; M Lautenschlager; A Bergk; J Katchanov; D Freyer; K Kapinya; U Herwig; D Megow; U Dirnagl; J R Weber; H Hörtnagl
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

10.  Caspase-3- and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta-amyloid-treated hippocampal neurons.

Authors:  S-Y Park; C Tournell; R C Sinjoanu; A Ferreira
Journal:  Neuroscience       Date:  2006-10-19       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.